RBC Capital Reiterates Outperform Rating on Axsome Therapeutics, Inc. (AXSM)

Market Context

Axsome Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $249.76 with a market capitalization of $7.5B. The stock has gained 130.1% over the past 52 weeks.

Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Axsome Therapeutics, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Axsome Therapeutics, Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 07, 2026	RBC Capital	Outperform	N/A
Jun 17, 2026	TD Cowen	Buy	N/A
May 05, 2026	RBC Capital	Outperform	N/A
May 05, 2026	Guggenheim	Buy	N/A
May 05, 2026	Mizuho	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View AXSM Stock Page